KDR and breast carcinoma: In this context, several inhibitors of the VEGF/VEGFR pathway such as the monoclonal antibodies bevacizumab and ramucirumab, as well as the TKIs sorafenib, sunitinib, vandetanib, axitinib, pazopanib, and cediranib, did not provide survival advantage in patients with breast cancer in clinical trials [4].